Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative therapies function by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to consumption. By activating GLP-1 receptors in the pancreas, these agents boost insulin production and suppres

The management of diabetes is with the emergence of exciting new therapies. Among these, Reta, GLP-1 receptor agonists, Retatrutide, and Trizepatide are gaining significant traction. These medications offer promising approaches for controlling blood sugar levels and may improve the lives of individuals living with diabetes. This novel class of dr